These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 7628338)

  • 21. [Treatment of schizophrenia from the viewpoint of the patient. Studies on the course of treatment and neuroleptic treatment from a personal perspective].
    Windgassen K
    Monogr Gesamtgeb Psychiatr Psychiatry Ser; 1989; 58():1-169. PubMed ID: 2576099
    [No Abstract]   [Full Text] [Related]  

  • 22. [Clozapine and treatment of negative symptoms].
    Lançon C; Farisse J; Llorca PM
    Encephale; 1997 Sep; 23 Spec No 4():7-11. PubMed ID: 9417403
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of clozapine on cognitive function in schizophrenia.
    Lee MA; Thompson PA; Meltzer HY
    J Clin Psychiatry; 1994 Sep; 55 Suppl B():82-7. PubMed ID: 7961582
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Medico-economic evaluation of treatment with clozapine versus treatment with previous neuroleptics].
    Geronimi-Ferret D; Lesay M; Barges-Bertocchio MH; Cornet-Bonnefont M; Robert H
    Encephale; 1997 Sep; 23 Spec No 4():24-31. PubMed ID: 9417402
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treating prodromal episodes to prevent relapse in schizophrenia.
    Herz MI; Glazer W; Mirza M; Mostert M; Hafez H
    Br J Psychiatry Suppl; 1989 Jul; (5):123-7. PubMed ID: 2574984
    [No Abstract]   [Full Text] [Related]  

  • 26. Experience with a drug-free month in schizophrenic outpatients.
    Heinrichs DW; Carpenter WT
    Psychopharmacol Bull; 1985; 21(1):117-9. PubMed ID: 2858904
    [No Abstract]   [Full Text] [Related]  

  • 27. Ideal and reality of neuroleptic relapse prevention.
    Kissling W
    Br J Psychiatry Suppl; 1992 Oct; (18):133-9. PubMed ID: 1356363
    [No Abstract]   [Full Text] [Related]  

  • 28. [What should we recommend for schizophrenic patients: long-term drug prevention or interval treatment?].
    Müller P
    Nervenarzt; 1983 Sep; 54(9):477-85. PubMed ID: 6138720
    [No Abstract]   [Full Text] [Related]  

  • 29. Fluvoxamine augmentation in clozapine-resistant schizophrenia: an open pilot study.
    Silver H; Kushnir M; Kaplan A
    Biol Psychiatry; 1996 Oct; 40(7):671-4. PubMed ID: 8886304
    [No Abstract]   [Full Text] [Related]  

  • 30. Conditioning in the prediction of drug withdrawal effects in chronic schizophrenic patients.
    Ban TA; Ananth JV; Lehmann HE
    Act Nerv Super (Praha); 1974 Mar; 16(1):23-33. PubMed ID: 4156144
    [No Abstract]   [Full Text] [Related]  

  • 31. [Drug management and therapy resistance. A cross-sectional study of schizophrenic patients in a large psychiatric hospital].
    Mohr F; Bender W; Hubmann W; Mäsel K; Pior R
    Psychiatr Prax; 1992 Jul; 19(4):108-13. PubMed ID: 1354878
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Information processing and maintenance dose requirements in schizophrenia.
    Marder SR; Asarnow RF; Van Putten T
    Psychopharmacol Bull; 1988; 24(2):247-50. PubMed ID: 2905506
    [No Abstract]   [Full Text] [Related]  

  • 33. [Sequence in prescribing neuroleptics: a therapeutic alternative in refractory schizophrenia?].
    Allouche G; Joober R; Vanelle JM; Brochier T; Olié JP
    Encephale; 1994; 20(6):777-80. PubMed ID: 7875112
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nifedipine in neuroleptic-refractory schizophrenia.
    Kramer MS; DeMaria P; Morrow R; DiJohnson C; Sheves P
    J Clin Psychopharmacol; 1987 Jun; 7(3):195-6. PubMed ID: 2885346
    [No Abstract]   [Full Text] [Related]  

  • 35. Predictors of neuroleptic treatment response in acute schizophrenia: results of a treatment study with perazine.
    Gaebel W; Pietzcker A; Ulrich G; Schley J; Müller-Oerlinghausen B
    Pharmacopsychiatry; 1988 Nov; 21(6):384-6. PubMed ID: 2907645
    [No Abstract]   [Full Text] [Related]  

  • 36. Neuroleptic dosing in chronic schizophrenia: a 10-year follow-up.
    Remington GJ; Prendergast P; Bezchlibnyk-Butler KZ
    Can J Psychiatry; 1997 Feb; 42(1):53-7. PubMed ID: 9040924
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Topiramate for refractory schizophrenia.
    Millson RC; Owen JA; Lorberg GW; Tackaberry L
    Am J Psychiatry; 2002 Apr; 159(4):675. PubMed ID: 11925318
    [No Abstract]   [Full Text] [Related]  

  • 38. Lower-dose therapy with traditional neuroleptics in chronically hospitalized schizophrenic patients.
    Smith RC
    Arch Gen Psychiatry; 1994 May; 51(5):427-9. PubMed ID: 7910013
    [No Abstract]   [Full Text] [Related]  

  • 39. Safety of clozapine in patient with treatment resistant schizophrenia & asymptomatic constitutional macrothrombocytopenia (Harris syndrome).
    Pathak H; Damodharan D; Jayasankar P; Sreeraj VS; Venkatasubramanian G
    Asian J Psychiatr; 2019 Oct; 45():121-122. PubMed ID: 31569026
    [No Abstract]   [Full Text] [Related]  

  • 40. Early intervention, time-limited, targeted pharmacotherapy of schizophrenia.
    Carpenter WT; Heinrichs DW
    Schizophr Bull; 1983; 9(4):533-42. PubMed ID: 6140752
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.